ALK Antibody (DA002)
ALK Antibody (DA002)
Recombinant monoclonal rabbit antibody
Description
Anaplastic lymphoma kinase (ALK) belongs to the insulin receptor superfamily. It is a transmembrane receptor protein-tyrosine kinase and it can create a fusion protein with the nuclear protein gene nucleophosmin (NPM). ALK can be active in cancer through multiple mechanisms. The protein expression by tumor cells is an independent prognostic factor that predicts a favorable outcome. ALK staining is positive in about 60% of anaplastic large cell lymphoma (ALCL). Various solid tumors, such as non-small cell lung carcinoma (NSCLC) and brain cancers were also found to aberrantly express the protein. 1-7
References
1. Cessna MH, Zhou H, Sanger WG et al. (2002) Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod Pathol. 15(9):931-8.
2. Gascoyne RD, Aoun P, Wu D et al. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999. 93(11):3913-21
3. Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001. 20(40):5623-37.
4. Li S (2009) Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. Int J Clin Exp Pathol. 2(6):508-18.
5. Morgan EA and Nascimento AF (2012) Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv Hematol. 2012:529572.
6. Sukov WR, Cheville JC, Carlson AW et al (2007) Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol. 20(5):592-603.
7. Pulford K, Lamant L, Morris SW et al (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 89(4):1394-404.
2. Gascoyne RD, Aoun P, Wu D et al. (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999. 93(11):3913-21
3. Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001. 20(40):5623-37.
4. Li S (2009) Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity. Int J Clin Exp Pathol. 2(6):508-18.
5. Morgan EA and Nascimento AF (2012) Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. Adv Hematol. 2012:529572.
6. Sukov WR, Cheville JC, Carlson AW et al (2007) Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol. 20(5):592-603.
7. Pulford K, Lamant L, Morris SW et al (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood. 89(4):1394-404.
Specifications
Application:
IHC (FFPE)
Host:
Rabbit
Subclass:
IgG
Immunogen:
Synthetic peptide from human ALK
Cellular location:
Cytoplasm/Nucleus
Control:
Anaplastic large cell lymphoma
Order information
| RMB1A001 | Concentrate | IVD(R) |
| RMB1A001 | 10 ml Ready to use | IVD(R) |
| RMB1A001 | 6 ml Ready to use | IVD(R) |
| RMB1A001 | 3 ml Ready to use | IVD(R) |
